List of Implants Companies in Massachusetts - 29

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

This unique mechanical surgical clamping technology is delivered directly through a fine, minimally invasively, 18 G needle for clamping of blood vessels, ducts, arteries, and veins. The minimally invasive needle delivery results in secure occlusion similar to that of a transfixion suture. SCureClamp with iDOT's anchoring feature secures the implant in place and eliminates slippage. Grasping allows physicians to occlude vessels of varying sizes, types, and wall thickness.

Developing seamless neural interfaces.

Biostage is a biotechnology company that focuses on developing organ replacement therapies using cellular scaffolds and tissue engineering.

BioSurfaces, based in Ashland, Massachusetts, is a life science company with deep leadership and a diverse team of specialists. The company's proprietary electrospinning technology known as Bio-Spun™ creates product solutions by engineering biology with synthetic cellular matrices for applications ranging from IVRT and delivery of bio-active therapeutics to medical devices and consumer health products. These materials can be made to form a variety of unusual and difficult-to-manufacture shapes while also demonstrating improved biocompatibility over other textile-based materials. The BioSurfaces manufacturing process also allows the incorporation of drugs or other bioactive agents directly into the nanofibers for localized release. BioSurfaces' technology is validated by leading organizations in pharmaceuticals, medical devices, life sciences, and consumer products.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

Our Mission Patients vary in more ways than gender, race, and size. At Conformis, we believe that optimizing implant fit and performance requires a personalized approach. Our mission is to provide best-in-class, personalized joint replacement systems and instrumentation that offer unique advantages over traditional orthopedic implants. We pioneered full personalization with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. Our fully personalized implants are individually sized and shaped to fit to each patient’s unique anatomy, providing precise anatomic fit and preserving healthy tissue. Our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. By combining our personalized implants with our unique instrumentation, a surgeon is able to provide a solution that preserves more of a patient’s joint and minimizes surgical trauma. Our Company Conformis, Inc. is a publicly traded medical device company based in Massachusetts. It was founded in 2004 to provide dramatic advancements in patient care by utilizing imaging technology to create personalized, patient-specific implants and instrumentation.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

CystoSure is a novel device specifically designed for safe, efficient and standardized visualization of the female bladder and ureteral openings. Building off of a traditional Foley catheter design, CystoSure introduces a whole new means of safely and comfortably evaluating the female bladder.

Freudenberg Medical is a global partner for the design, development and manufacture of medical devices, components, and minimally invasive product solutions. Our comprehensive technical capabilities range from the design and manufacture of minimally invasive, catheter, and handheld technology to the development and production of medical components utilizing advanced materials and processes. We are an industry leader in the manufacture of high precision silicone and thermoplastic components and tubing as well as metal hypotubes and coating technology. Freudenberg Medical is part of the Freudenberg Group, a global technology group. As an organization, we ensure that every project is supported by our unmatched range of global resources, financial stability, and the flexibility to optimize for business performance. www.FreudenbergMedical.com Explore the possibilities with Freudenberg Medical, please call 877-308-0558 or email info@freudenbergmedical.com

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. We sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including GE Healthcare, Thermo Fisher Scientific Inc., and VWR. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, and Spain and sales facilities in France and Canada.

InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is currently in clinical trials testing its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality.

inQB8 is a med-tech incubator founded in 2018 to develop novel, device-based solutions for the biggest cardiovascular challenges and create successful start-ups that can bring those solutions to the patients that need them most.

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

Mass Eye and Ear in Boston is a Harvard teaching hospital dedicated to eye (ophthalmology) and ear, nose, throat, head and neck (ENT) care and research.

Developer of bio-engineered surgical implants designed to facilitate new tissue growth and also aid in connective tissue repair. The company's implants specialize in viable alternatives to conventional ACL reconstruction for patients who have sustained any kind of leg injury, enabling surgeons to perform surgery to restore normal anatomy and function of the knee.

Nanofuse is a regenerative therapeutic that has the properties of replacing or "regenerating" human bone cells to form normal bone. NanoFUSE Biologics products contain the only bioactive glass that is FDA-Cleared to be combined with demineralized bone matrix (DBM). The regenerative efficacy comes from the osteoinductivity of the DBM component plus the osteopromotivity of the bioactive glass. Bioactive glass has been clinically proven for over 30 years but only until now has NanoFUSE Biologics used bioactive glass to create a revolutionary and patented regenerative therapeutic.

NanoHive Medical (formerly HD LifeSciences) created the proprietary, biomimetic Soft Titanium technology, which clearly distinguishes their products in the $1.9B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provides surgeons and their patients with the ideal features that lead to consistently strong fusion constructs and efficacious clinical experiences.

NeuroBionics is pioneering the future of precision bioelectronic medicine by developing the next generation of implantable devices, designed to seamlessly interface with the human body. Our core technology lies in flexible, multifunctional fibers the size of a human hair, which can record and stimulate neural activity, deliver drugs, and ablate tissue. Using an endovascular approach, we will navigate our microscopic-sized flexible fiber implant through the intricate network of blood vessels to deliver precise therapeutic intervention to neural tissue. By making neural interfacing a minimally-invasive procedure, we will revolutionize deep brain stimulation and broaden access to this lifechanging therapy. By doing so, we aim to improve the lives of millions grappling with conditions like Parkinson's disease, essential tremor, epilepsy, and depression.

Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio's mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology. OSSIOfiber™ represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore mobility with nothing permanent left behind. Our products have the mechanical strength needed for easy insertion and secure fixation while enabling the body to regrow bone, completely incorporating and replacing the implant without the adverse inflammation and weakness often seen in “bio-resorbables”.

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

At Satellite Bio, we’re on a journey – a quest to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine. With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases. Satellite Bio’s quest is as audacious as it is clear: bring new hope to patients and families suffering from elusive diseases. Tissue Therapeutics is how it will deliver on that promise—and why it is deeply committed to leading and realizing the potential of this exciting new frontier in regenerative medicine.

ZSFab dedicates to produce high performance, low-cost, customized medical implants, surgical guides and anatomical models. We are developing unique solutions that integrate our own software tools, advanced modeling and optimization methods, and 3D printing technology. Each of us is born unique, and such uniqueness is imprinted in our DNA and reflected in our finger print, our face, our bone. Such uniqueness requires that when the part is worn, damaged, or aged, the replacement shall be the same. With the help of additive manufacturing, ZSFab is to structure, design, print the best medical implants and assist in the healing process. ZSFab has the goal to provide the solutions for health care, including surgical process. With the products of ZSFab, we will help to ease the burden of the doctors and release our customers of prolonged pain. In ZSFab, we believe: all men are created equal, but shall be treated differently, when it comes to healthcare.